Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

VOLUNTARY ANNOUNCEMENT - ABSTRACTS ON USING TRANSLATIONAL TGI MODEL AND POPULATION PK ANALYSIS FOR KN026 ACCEPTED FOR POSTER PRESENTATION AT 2020 AACR ANNUAL MEETING 2020-05-18
ABSTRACTS ON PRELIMINARY RESULTS FROM CLINICAL TRIALS OF KN035 ACCEPTED FOR POSTER PRESENTATION AT 2020 ASCO ANNUAL MEETING 2020-05-15
VOLUNTARY ANNOUNCEMENT - ABSTRACTS ON PRELIMINARY RESULTS FROM CLINICAL TRIALS OF KN026 AND KN046 ACCEPTED FOR POSTER PRESENTATION AT 2020 ASCO ANNUAL MEETING 2020-05-14
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2020 2020-05-06
2019 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2020-04-22
NOTICE OF ANNUAL GENERAL MEETING 2020-04-21
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING 2020-04-21
(1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; (2) PROPOSED ADOPTION OF POST-IPO SHARE OPTION SCHEME; (3) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (4) PROPOSED RE-APPOINTMENT OF AUDITORS; AND(5) NOTICE OF ANNUAL GENERAL MEETING 2020-04-21
2019 Annual Report 2020-04-21
VOLUNTARY ANNOUNCEMENT - JIANGSU ALPHAMAB RECEIVED THE SAFE TO PROCEED LETTER FROM THE U.S. FDA FOR A PHASE II CLINICAL TRIAL OF KN046 FOR NSCLC IN THE UNITED STATES 2020-04-15

21 22 23 24 25 26 27